Biotechnology exchange traded funds (ETFs) are moving higher this morning after speculation that GlaxoSmithKline (GSK) could make an offer to take over Human Genome Sciences (HGSI). Here are more stories on the subject that may interest you:

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.